Showing results (61-70 of 482) with videos related to
Sort By:
Pageof 49
Anticancer Research|November 11, 2006
Meta-analysis and pooled re-analysis of copy number changes in colorectal cancer detected by comparative genomic hybridizationSimon Hughes, Richard D Williams, Emily Webb, et al.Scientific Reports|September 23, 2015
Genome-wide homozygosity signature and risk of Hodgkin lymphomaAmit Sud, Rosie Cooke, Anthony J Swerdlow, et al.Best Practice & Research. Clinical Haematology|November 29, 2015
Long-term follow-up after purine analogue therapy in hairy cell leukaemiaMonica Else, Claire E Dearden, Daniel CatovskyMedical Oncology (Northwood, London, England)|August 16, 2002
Alemtuzumab in T-cell malignanciesClaire E Dearden, Estella Matutes, Daniel CatovskyBMC Cancer|November 8, 2017
Constitutional mutation in CDKN2A is associated with long term survivorship in multiple myeloma: a case reportVallari Shah, Kevin D Boyd, Richard S Houlston, et al.Leukemia & Lymphoma|May 24, 2011
Long-term results for pentostatin and cladribine treatment of hairy cell leukemiaClaire E Dearden, Monica Else, Daniel CatovskyPlos One|May 12, 2011
Chromosome 15q25 (CHRNA3-CHRNA5) variation impacts indirectly on lung cancer riskYufei Wang, Peter Broderick, Athena Matakidou, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 7, 2017
Risk of Second Cancer in Hodgkin Lymphoma Survivors and Influence of Family HistoryAmit Sud, Hauke Thomsen, Kristina Sundquist, et al.International Journal of Cancer|March 22, 2006
Evaluation of xeroderma pigmentosum XPA, XPC, XPD, XPF, XPB, XPG and DDB2 genes in familial early-onset lung cancer predispositionAthena Matakidou, Tim Eisen, Christina Fleischmann, et al.Lung Cancer (Amsterdam, Netherlands)|January 2, 2009
Plasminogen activator inhibitor variants PAI-1 A15T and PAI-2 S413C influence lung cancer prognosisMaria Chiara Di Bernardo, Athena Matakidou, Tim Eisen, et al.Pageof 49